Research Peptide Quality Agreement: A Practical Template and the Clauses That Matter

B2B Sourcing | 2026-07-09 | 11 min read

How to draft a research peptide quality agreement that protects the buyer, what clauses are non-negotiable, which ones are usually over-lawyered, and how to align the QA with the master supply agreement.

The most-misunderstood document in peptide procurement

A quality agreement is the document a procurement manager signs once, files, and never reads again — until a COA fails acceptance. By then, the missing clauses are a much bigger problem than the missing peptide vials.

A well-drafted quality agreement does three things:

• Defines what the supplier's quality system must produce
• Defines how the buyer accepts or rejects each lot
• Defines what happens when something goes wrong

If any of the three is vague, the agreement does not protect the buyer.

Quality agreement vs. master supply agreement

These are two different documents that work together:

| Document | Scope | | --- | --- | | Master Supply Agreement (MSA) | Pricing, payment, lead time, liability, force majeure, dispute resolution | | Quality Agreement (QA) | COA scope, deviation handling, audit rights, change control, retention |

Most institutional buyers keep the two separate because commercial and quality teams negotiate them on different cycles. The QA usually references the MSA by name and is incorporated as a schedule.

The seven sections a peptide QA must contain

• **Scope and purpose** — what the agreement covers and what it excludes
• **Roles and responsibilities** — supplier's quality deliverables and buyer's acceptance duties
• **COA specification** — what the COA must contain, who signs it, how it is delivered
• **Deviation handling** — what counts as a deviation, who notifies, by when, with what information
• **Change control** — how the supplier informs the buyer of process changes
• **Audit rights** — who can audit, when, with what notice
• **Records and retention** — how long COAs and supporting data are kept

Each section is a real clause, not a heading. Skipping any one of them creates a real risk.

Section 1 — Scope and purpose

Spell out what the QA covers:

• Specific compounds or product families
• Manufacturing sites
• Quality system (typically ISO 9001 or equivalent)
• Period of coverage (typically 1-3 years, auto-renewing)

Equally important: what the QA does not cover. The QA typically does not cover research use outcomes, regulatory approvals for human use, or product liability once the vial leaves the supplier's site.

Section 2 — Roles and responsibilities

The supplier is responsible for:

• Synthesis against an agreed specification
• In-process and release testing
• COA generation and delivery
• Deviation reporting
• Record retention

The buyer is responsible for:

• Acceptance review against the QA scope
• Independent verification (if specified)
• Quarantine and release decisions
• Storage and handling compliance

The asymmetry matters. The supplier produces, the buyer accepts. Both must know their side.

Section 3 — COA specification

This is the most important section. Specify:

• Purity method (HPLC with column, gradient, detection wavelength)
• Purity acceptance threshold (typically ≥98% for research, ≥99% for receptor work)
• Identity method (MS with mass error threshold in ppm)
• Endotoxin method (LAL kinetic chromogenic or rFC) and limit
• Residual solvent panel against ICH Q3C
• Visual description target
• Lot number format and traceability
• Sign-off requirement (analyst name, date, signature)
• Delivery method (PDF, secure portal, EDI)

A QA that does not pin down the COA scope is not a QA.

Section 4 — Deviation handling

A deviation is any event that could affect product quality. The QA must define:

• What counts as a deviation (out-of-spec result, process excursion, equipment failure)
• Notification timeline (typically 24-48 hours)
• Notification content (lot affected, deviation summary, preliminary impact assessment)
• Investigation timeline
• Joint decision process (hold, rework, release, reject)
• Documentation requirement (deviation report, root cause, corrective action)

Most disputes arise from deviation handling. Pin it down.

Section 5 — Change control

The supplier's synthesis process is not static. The QA must define how the buyer is informed of:

• Amino acid supplier changes
• Synthesis scale changes
• Purification method changes
• Packaging component changes
• Manufacturing site changes
• Quality system changes

Critical changes typically require buyer consent. Non-critical changes require notification only. The QA must specify which is which.

Section 6 — Audit rights

The buyer should have the right to audit the supplier's quality system. The QA must define:

• Audit frequency (typically annual for institutional programs)
• Notice period (typically 30 days)
• Audit scope (the supplier's site or paper audit only)
• Cost allocation (each side pays its own costs)
• Confidentiality of audit findings
• Corrective action follow-up process

A QA without audit rights is a wish list, not an agreement.

Section 7 — Records and retention

The supplier must retain:

• Synthesis batch records (typically 5+ years)
• Analytical raw data (chromatograms, spectra)
• COA copies
• Deviation reports
• Calibration records
• Training records for analysts

The retention period usually matches the buyer's publication horizon, which for research peptides is often 5-10 years.

Clauses that are usually over-lawyered

Some clauses get negotiated hard but rarely matter. Watch for:

• Force majeure definitions broader than the MSA allows
• Indemnification language extending to product liability after acceptance
• Termination for convenience with no cure period
• Audit rights that allow full unrestricted access without notice

These are typically settled in the first QA cycle and rarely revisited unless the relationship sours.

How ZePeptide supports QA negotiations

ZePeptide provides a baseline quality agreement that:

• Defines COA scope with chromatogram and mass spec required
• Sets 24-hour deviation notification and 5-day investigation timeline
• Includes annual audit right with 30-day notice
• Establishes 5-year minimum record retention
• Defines change control categories and consent thresholds

Customize the operational clauses to your program. Most institutional buyers add their own deviation notification content, audit cost allocation, and termination clauses.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.